Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM338 in IgA Nephropathy
NCT05775042Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- May 2023
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CM338 in IgA nephropathy (IgAN), sponsored by Keymed Biosciences. Started May 2023; status: recruiting.
02
Drugs
CM338
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05775042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775042.